Rare Disease : Episode 15

Video

Episode 16 - Factors Hindering Care for SLE Patients

Despite the number of drugs currently in the pipeline for the treatment of systemic lupus erythematosus (SLE), the panelists raise concerns about unaddressed factors that may continue to impede a clinician’s decision to recommend a treatment option to a patient.

Michelle Petri, MD, MPH, explains that newly-approved therapy options still lack personalized biomarkers and do not provide important long-term outcomes data that help professionals make decisions about treatment for patients with SLE.

Patrick F. Fogarty, MD, further explains that when defining the value of medical therapy, an economic consideration continues to stand in the way of treatment recommendations.

Without addressing these issues, Dr Petri and Dr Fogarty agree that when selecting appropriate therapy for a patient, and when considering the costs associated with a treatment option, it is important to individualize therapy for patients with SLE.


Related Videos
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Pierluigi Porcu, MD
Image credit: Medical technology and futuristic concept. Doctor hologram modern virtual screen interface | SOMKID - stock.adobe.com
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Elizabeth Grush, MBA
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Erin Weber, MS
Kenny Cole, MD
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo